NEWS & EVENTS

CURRENT NEWS

February 3, 2016

Morphotek Announces Collaboration with Mayo Clinic to Apply its Folate Receptor Alpha Diagnostic Assays in A Phase II Clinical Trial in Triple-Negative Breast Cancer
Read More

December 16, 2015

Morphotek, Inc. Announces an Agreement With Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Read More

December 11, 2015

Morphotek's Run to Bring Hope Home
Read More

December 7, 2015

Morphotek Announces Phase 1 Results From MORAb-022-001 Trial in Healthy Subjects and Patients with Mild-to-Moderate Rheumatoid Arthritis
Read More

December 3, 2015

Morphotek Announces Collaboration Agreement with University of Wisconsin-Madison to Study the Immunosuppressive Effects of CA125 Tumor Antigen on Immune-Based Therapies for Ovarian Cancer
Read More

November 18, 2015

Morphotek, Inc. Announces Initiation of Amatuximab Study in First-Line, Unresectable, Malignant Pleural Mesothelioma Patients
Read More

November 17, 2015

Morphotek Announces Collaboration Agreement With University of Gothenburg to Develop Farletuzumab, an Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, for Alpha-Particle Radioimmunotherapy in Ovarian Cancer
Read More

November 9, 2015

Morphotek, Inc. Announces a License Agreement With Blaze Bioscience Inc. For The Development of Novel Oncology Imaging Technology
Read More